Indian Generics Global Public Good: Pharma Diplomacy & Trade Strategy
Kartavya Desk Staff
Syllabus: Pharma Industry
Source: TH
Context: India’s pharmaceutical exports face pressure as the U.S. imposes tariffs and stricter IP demands, threatening the viability of Indian generics in their biggest market. Despite this, Indian generics remain the backbone of affordable healthcare worldwide, saving billions in costs.
About Indian Generics Global Public Good: Pharma Diplomacy & Trade Strategy
Current Pharma Status:
• India is the largest supplier of generics to over 200 countries, cementing its role as the “Pharmacy of the World.”
• The U.S. accounts for 31.35% of India’s pharma exports and imports 47% of its generics from India.
• In 2022, Indian generics saved the U.S. USD 219 billion in healthcare expenditure.
• The global generics market will hit USD 614 billion by 2030, with India as a leading player.
• Challenges include U.S. tariffs, dependence on Chinese APIs, and rising global competition in generics.
Significance of Indian Generics:
• Affordable Medicines: Indian generics are 20–25% of branded prices, making drugs for diabetes, cancer, HIV, etc., accessible worldwide.
• Global Public Health: They form over 90% of prescriptions in the U.S. and are critical for developing nations.
• Economic Role: Pharma exports contribute ~USD 25 billion annually and generate millions of jobs in India.
• Strategic Leverage: Generics boost India’s global soft power, evident in initiatives like Vaccine Maitri during COVID-19.
• Innovation Potential: India is emerging as a leader in biosimilars, vaccines, and low-cost R&D-based pharma solutions.
Need for Strategic Shift:
• India must move beyond short-term tariff concessions to long-term strategic positioning in trade negotiations.
• Strongly resist TRIPS-plus demands that would extend drug monopolies and delay entry of low-cost generics.
• Reduce dependence on U.S. markets by expanding exports to Africa, Latin America, ASEAN, and Central Asia.
• Ensure technology transfer and joint R&D in exchange for pricing concessions to strengthen domestic pharma capacity.
• Position Indian generics as a global public good, aligning trade policy with SDG-3: Health for All.
Challenges:
• Trade Barriers: U.S. levying 26% tariff + 25% penalty on imports. Push for zero tariffs in bilateral negotiations without reciprocal benefits.
• U.S. levying 26% tariff + 25% penalty on imports.
• Push for zero tariffs in bilateral negotiations without reciprocal benefits.
• IPR Pressures: Demands for stronger patent protections beyond TRIPS. Push for data exclusivity and extended monopolies, delaying generic entry.
• Demands for stronger patent protections beyond TRIPS.
• Push for data exclusivity and extended monopolies, delaying generic entry.
• Domestic Constraints: Dependence on China for APIs (Active Pharmaceutical Ingredients). Regulatory hurdles and fragmented R&D ecosystem.
• Dependence on China for APIs (Active Pharmaceutical Ingredients).
• Regulatory hurdles and fragmented R&D ecosystem.
• Global Competition: Rise of alternative hubs in China, Brazil, Eastern Europe.
• Public Health Risks: Restrictive IP rules would increase medicine prices globally, worsening inequity.
Initiatives & Policy Measures:
• TRIPS Flexibilities: India has maintained compulsory licensing provisions to ensure affordable medicines.
• India–US TRUST Initiative: For collaboration in biotech, pharma, and health technologies.
• Make in India + PLI Scheme for Pharma: To strengthen domestic production and reduce API dependence.
• South–South Cooperation: India exploring joint ventures in Africa, Latin America, and ASEAN.
• Health-Tech Diplomacy: Sharing vaccine platforms, generics technology with developing nations.
Way Forward:
• Leverage Negotiating Capital: Demand comprehensive review of TRIPS and resist TRIPS-plus provisions. Emphasise generics’ role in global health security post-COVID.
• Demand comprehensive review of TRIPS and resist TRIPS-plus provisions.
• Emphasise generics’ role in global health security post-COVID.
• Diversify Export Markets: Reduce overdependence on U.S. by expanding into Africa, Latin America, ASEAN, Central Asia.
• Reduce overdependence on U.S. by expanding into Africa, Latin America, ASEAN, Central Asia.
• Promote Joint Ventures: Encourage collaborations in the Global South and with EU/US firms for co-manufacturing & R&D.
• Encourage collaborations in the Global South and with EU/US firms for co-manufacturing & R&D.
• Strengthen Domestic Capacity: Invest in API self-reliance, R&D hubs, and regulatory reforms.
• Invest in API self-reliance, R&D hubs, and regulatory reforms.
• Use Public Health Diplomacy: Position generics as part of India’s soft power — like Vaccine Maitri. Build coalitions at WTO, WHO, and BRICS to counter Big Pharma monopolies.
• Position generics as part of India’s soft power — like Vaccine Maitri.
• Build coalitions at WTO, WHO, and BRICS to counter Big Pharma monopolies.
• Link Concessions with Tech Transfer: Any trade-off in pricing/export terms must be tied to technology sharing and local capacity-building.
• Any trade-off in pricing/export terms must be tied to technology sharing and local capacity-building.
Conclusion:
Indian generics are the lifeline of global healthcare, saving billions in costs and lives. India must reframe them as a global public good, resist unfair IP regimes, and diversify partnerships — safeguarding health worldwide while cementing its role as the Pharmacy of the Global South.